| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Defibrillators, Implantable | 70 | 2023 | 381 | 9.850 |
Why?
|
| Myocardial Infarction | 130 | 2023 | 1209 | 8.720 |
Why?
|
| Heart Failure | 137 | 2024 | 2324 | 7.930 |
Why?
|
| Cardiology | 64 | 2024 | 359 | 7.840 |
Why?
|
| Registries | 136 | 2024 | 2392 | 7.600 |
Why?
|
| Percutaneous Coronary Intervention | 51 | 2026 | 547 | 6.990 |
Why?
|
| Death, Sudden, Cardiac | 32 | 2021 | 230 | 6.170 |
Why?
|
| Atrial Appendage | 13 | 2024 | 36 | 4.550 |
Why?
|
| Atrial Fibrillation | 29 | 2024 | 555 | 4.150 |
Why?
|
| Primary Prevention | 24 | 2020 | 217 | 3.890 |
Why?
|
| American Heart Association | 45 | 2024 | 356 | 3.390 |
Why?
|
| Cardiac Resynchronization Therapy | 17 | 2023 | 63 | 3.040 |
Why?
|
| United States | 247 | 2026 | 16018 | 3.040 |
Why?
|
| Cardiovascular Diseases | 47 | 2024 | 2172 | 2.910 |
Why?
|
| Hospitalization | 77 | 2024 | 2446 | 2.860 |
Why?
|
| Medicare | 56 | 2024 | 899 | 2.850 |
Why?
|
| Quality of Health Care | 41 | 2024 | 692 | 2.770 |
Why?
|
| Aged | 282 | 2026 | 25955 | 2.630 |
Why?
|
| Stroke | 24 | 2024 | 1262 | 2.540 |
Why?
|
| Ventricular Dysfunction, Left | 18 | 2021 | 392 | 2.490 |
Why?
|
| Coronary Artery Disease | 23 | 2026 | 743 | 2.330 |
Why?
|
| Practice Guidelines as Topic | 35 | 2021 | 1569 | 2.260 |
Why?
|
| Patient Readmission | 31 | 2021 | 765 | 2.220 |
Why?
|
| Hospital Mortality | 51 | 2024 | 1033 | 2.180 |
Why?
|
| Hospitals | 33 | 2024 | 729 | 2.170 |
Why?
|
| Aged, 80 and over | 126 | 2024 | 8283 | 2.140 |
Why?
|
| Secondary Prevention | 14 | 2021 | 255 | 2.110 |
Why?
|
| Humans | 493 | 2026 | 144665 | 2.070 |
Why?
|
| Quality Indicators, Health Care | 27 | 2021 | 335 | 1.990 |
Why?
|
| Quality Assurance, Health Care | 27 | 2015 | 341 | 1.880 |
Why?
|
| Risk Assessment | 63 | 2024 | 3729 | 1.860 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 31 | 2023 | 228 | 1.820 |
Why?
|
| Exercise Test | 18 | 2021 | 626 | 1.820 |
Why?
|
| Societies, Medical | 21 | 2024 | 890 | 1.810 |
Why?
|
| Male | 311 | 2026 | 72425 | 1.790 |
Why?
|
| Treatment Outcome | 112 | 2025 | 11734 | 1.760 |
Why?
|
| Adrenergic beta-Antagonists | 28 | 2018 | 251 | 1.730 |
Why?
|
| Electric Countershock | 11 | 2019 | 127 | 1.720 |
Why?
|
| Female | 311 | 2026 | 78301 | 1.700 |
Why?
|
| Risk Factors | 107 | 2024 | 10796 | 1.670 |
Why?
|
| Stroke Volume | 34 | 2024 | 650 | 1.580 |
Why?
|
| Sex Factors | 34 | 2020 | 2104 | 1.580 |
Why?
|
| Acute Coronary Syndrome | 8 | 2024 | 295 | 1.500 |
Why?
|
| Middle Aged | 178 | 2026 | 35968 | 1.470 |
Why?
|
| Arrhythmias, Cardiac | 10 | 2020 | 355 | 1.420 |
Why?
|
| Anti-Arrhythmia Agents | 7 | 2018 | 141 | 1.410 |
Why?
|
| Cardiac Catheterization | 13 | 2024 | 557 | 1.380 |
Why?
|
| Patient Discharge | 28 | 2023 | 985 | 1.370 |
Why?
|
| Forecasting | 6 | 2022 | 391 | 1.350 |
Why?
|
| China | 43 | 2022 | 269 | 1.340 |
Why?
|
| Electrocardiography | 19 | 2020 | 664 | 1.340 |
Why?
|
| Retrospective Studies | 119 | 2023 | 17147 | 1.330 |
Why?
|
| Coronary Artery Bypass | 12 | 2026 | 267 | 1.290 |
Why?
|
| Quality Improvement | 19 | 2024 | 1287 | 1.260 |
Why?
|
| Acute Kidney Injury | 13 | 2024 | 869 | 1.260 |
Why?
|
| Myocardial Ischemia | 10 | 2019 | 285 | 1.220 |
Why?
|
| Coronary Disease | 13 | 2019 | 381 | 1.220 |
Why?
|
| Health Status | 20 | 2020 | 834 | 1.220 |
Why?
|
| Time Factors | 68 | 2024 | 7140 | 1.170 |
Why?
|
| Practice Patterns, Physicians' | 21 | 2019 | 1360 | 1.160 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 11 | 2022 | 68 | 1.140 |
Why?
|
| Healthcare Disparities | 15 | 2024 | 736 | 1.120 |
Why?
|
| Advisory Committees | 14 | 2021 | 228 | 1.110 |
Why?
|
| Patient Selection | 21 | 2026 | 727 | 1.110 |
Why?
|
| Fee-for-Service Plans | 8 | 2021 | 99 | 1.100 |
Why?
|
| Ventricular Function, Left | 17 | 2022 | 536 | 1.080 |
Why?
|
| Follow-Up Studies | 57 | 2021 | 5414 | 1.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 14 | 2020 | 438 | 1.030 |
Why?
|
| Home Care Services | 7 | 2019 | 280 | 1.020 |
Why?
|
| Anemia | 9 | 2017 | 189 | 1.010 |
Why?
|
| Guideline Adherence | 19 | 2020 | 586 | 1.010 |
Why?
|
| Decision Support Techniques | 8 | 2021 | 461 | 0.990 |
Why?
|
| Hypertension | 17 | 2022 | 1262 | 0.970 |
Why?
|
| Angina Pectoris | 9 | 2018 | 75 | 0.970 |
Why?
|
| Survival Rate | 38 | 2021 | 2089 | 0.960 |
Why?
|
| Thiazolidinediones | 5 | 2010 | 139 | 0.940 |
Why?
|
| Age Factors | 37 | 2021 | 3329 | 0.940 |
Why?
|
| Cohort Studies | 53 | 2024 | 5957 | 0.930 |
Why?
|
| Myocardial Reperfusion | 8 | 2016 | 57 | 0.930 |
Why?
|
| Hospital Costs | 3 | 2019 | 125 | 0.920 |
Why?
|
| Aspirin | 14 | 2022 | 402 | 0.920 |
Why?
|
| Length of Stay | 14 | 2020 | 1339 | 0.910 |
Why?
|
| Patient Care | 2 | 2020 | 118 | 0.900 |
Why?
|
| Bradycardia | 3 | 2021 | 61 | 0.900 |
Why?
|
| Diabetes Mellitus | 17 | 2022 | 1076 | 0.890 |
Why?
|
| Angioplasty, Balloon, Coronary | 12 | 2012 | 155 | 0.890 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 5 | 2019 | 16 | 0.880 |
Why?
|
| Clinical Decision-Making | 9 | 2021 | 360 | 0.870 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 6 | 2020 | 18 | 0.870 |
Why?
|
| Ambulatory Care | 7 | 2020 | 607 | 0.870 |
Why?
|
| Evidence-Based Medicine | 13 | 2019 | 732 | 0.870 |
Why?
|
| Postoperative Hemorrhage | 5 | 2021 | 104 | 0.860 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2025 | 1742 | 0.850 |
Why?
|
| Coronary Angiography | 12 | 2024 | 324 | 0.850 |
Why?
|
| Quality of Life | 21 | 2020 | 3183 | 0.800 |
Why?
|
| Pacemaker, Artificial | 4 | 2021 | 126 | 0.790 |
Why?
|
| Antihypertensive Agents | 9 | 2022 | 512 | 0.780 |
Why?
|
| Survival Analysis | 22 | 2021 | 1370 | 0.780 |
Why?
|
| Multimorbidity | 2 | 2021 | 64 | 0.780 |
Why?
|
| Insurance, Health | 4 | 2021 | 308 | 0.770 |
Why?
|
| Disease Management | 10 | 2021 | 650 | 0.750 |
Why?
|
| ST Elevation Myocardial Infarction | 7 | 2021 | 64 | 0.750 |
Why?
|
| Hypoglycemic Agents | 15 | 2025 | 1388 | 0.740 |
Why?
|
| Tachycardia, Ventricular | 3 | 2019 | 180 | 0.720 |
Why?
|
| Multivariate Analysis | 32 | 2018 | 1537 | 0.710 |
Why?
|
| Heart Diseases | 7 | 2020 | 341 | 0.700 |
Why?
|
| Myocardial Revascularization | 11 | 2018 | 84 | 0.700 |
Why?
|
| Incidence | 27 | 2021 | 2892 | 0.700 |
Why?
|
| Data Accuracy | 1 | 2022 | 65 | 0.700 |
Why?
|
| Research Report | 7 | 2021 | 86 | 0.700 |
Why?
|
| Odds Ratio | 22 | 2018 | 1076 | 0.690 |
Why?
|
| Cross-Sectional Studies | 38 | 2023 | 5869 | 0.690 |
Why?
|
| Text Messaging | 5 | 2025 | 183 | 0.690 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 4 | 2024 | 26 | 0.690 |
Why?
|
| Creatinine | 13 | 2024 | 509 | 0.690 |
Why?
|
| Social Responsibility | 3 | 2016 | 53 | 0.680 |
Why?
|
| Clinical Trials as Topic | 10 | 2022 | 1056 | 0.670 |
Why?
|
| Radial Artery | 1 | 2021 | 72 | 0.660 |
Why?
|
| Insurance Carriers | 1 | 2021 | 13 | 0.660 |
Why?
|
| Prognosis | 33 | 2024 | 4312 | 0.640 |
Why?
|
| Health Care Costs | 5 | 2019 | 425 | 0.620 |
Why?
|
| Cardiac Output, Low | 6 | 2006 | 53 | 0.620 |
Why?
|
| Hemorrhage | 11 | 2024 | 813 | 0.610 |
Why?
|
| Logistic Models | 25 | 2018 | 2114 | 0.610 |
Why?
|
| Minority Groups | 3 | 2026 | 283 | 0.600 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 267 | 0.590 |
Why?
|
| Prospective Studies | 42 | 2024 | 7994 | 0.590 |
Why?
|
| Hyperglycemia | 9 | 2025 | 374 | 0.580 |
Why?
|
| Cardiovascular Agents | 5 | 2021 | 165 | 0.570 |
Why?
|
| Spironolactone | 4 | 2022 | 39 | 0.560 |
Why?
|
| Prostheses and Implants | 2 | 2020 | 141 | 0.560 |
Why?
|
| Delivery of Health Care | 6 | 2020 | 944 | 0.560 |
Why?
|
| Patient Admission | 11 | 2019 | 220 | 0.550 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2018 | 657 | 0.540 |
Why?
|
| Transcatheter Aortic Valve Replacement | 4 | 2021 | 153 | 0.530 |
Why?
|
| Comorbidity | 26 | 2019 | 1652 | 0.530 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 431 | 0.530 |
Why?
|
| Cardiologists | 1 | 2017 | 47 | 0.520 |
Why?
|
| Drug Prescriptions | 9 | 2018 | 283 | 0.520 |
Why?
|
| Health Policy | 9 | 2017 | 398 | 0.520 |
Why?
|
| Databases, Factual | 13 | 2020 | 1494 | 0.520 |
Why?
|
| Hemoglobins | 7 | 2017 | 381 | 0.510 |
Why?
|
| Predictive Value of Tests | 22 | 2018 | 2117 | 0.500 |
Why?
|
| Research Design | 12 | 2022 | 1129 | 0.490 |
Why?
|
| Cardiac Surgical Procedures | 6 | 2018 | 609 | 0.480 |
Why?
|
| Glomerular Filtration Rate | 8 | 2023 | 764 | 0.480 |
Why?
|
| Echocardiography, Stress | 5 | 2018 | 29 | 0.480 |
Why?
|
| Intra-Aortic Balloon Pumping | 3 | 2021 | 19 | 0.480 |
Why?
|
| Patient Transfer | 5 | 2019 | 208 | 0.470 |
Why?
|
| Chest Pain | 5 | 2020 | 99 | 0.470 |
Why?
|
| Platelet Aggregation Inhibitors | 10 | 2021 | 496 | 0.470 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2025 | 2573 | 0.470 |
Why?
|
| Angina, Unstable | 4 | 2016 | 82 | 0.460 |
Why?
|
| Health Resources | 1 | 2017 | 130 | 0.460 |
Why?
|
| Angiotensin Receptor Antagonists | 8 | 2023 | 115 | 0.460 |
Why?
|
| Diabetic Angiopathies | 5 | 2018 | 262 | 0.450 |
Why?
|
| Blood Pressure | 11 | 2022 | 1766 | 0.440 |
Why?
|
| Benchmarking | 5 | 2021 | 189 | 0.440 |
Why?
|
| Endovascular Procedures | 1 | 2020 | 385 | 0.440 |
Why?
|
| Proportional Hazards Models | 19 | 2019 | 1322 | 0.440 |
Why?
|
| Health Status Disparities | 6 | 2024 | 318 | 0.440 |
Why?
|
| Septal Occluder Device | 1 | 2015 | 37 | 0.430 |
Why?
|
| Metformin | 5 | 2007 | 320 | 0.430 |
Why?
|
| Machine Learning | 5 | 2021 | 587 | 0.430 |
Why?
|
| Cardiomyopathies | 2 | 2015 | 334 | 0.430 |
Why?
|
| Health Services Research | 2 | 2007 | 392 | 0.430 |
Why?
|
| Blood Glucose | 11 | 2025 | 2326 | 0.420 |
Why?
|
| Patient-Centered Care | 7 | 2019 | 545 | 0.410 |
Why?
|
| Mortality | 7 | 2019 | 377 | 0.400 |
Why?
|
| Postoperative Complications | 6 | 2019 | 2950 | 0.400 |
Why?
|
| Torsades de Pointes | 1 | 2013 | 23 | 0.400 |
Why?
|
| Heart Function Tests | 4 | 2019 | 59 | 0.390 |
Why?
|
| Medication Adherence | 8 | 2019 | 540 | 0.390 |
Why?
|
| Narcotics | 1 | 2013 | 58 | 0.390 |
Why?
|
| Syncope | 1 | 2013 | 56 | 0.390 |
Why?
|
| Equipment Design | 4 | 2017 | 527 | 0.390 |
Why?
|
| Shock, Cardiogenic | 5 | 2021 | 64 | 0.390 |
Why?
|
| Hemostasis, Surgical | 1 | 2013 | 25 | 0.380 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2021 | 197 | 0.380 |
Why?
|
| Health Expenditures | 4 | 2019 | 194 | 0.370 |
Why?
|
| Prosthesis Implantation | 4 | 2019 | 154 | 0.360 |
Why?
|
| Blood Loss, Surgical | 1 | 2013 | 110 | 0.360 |
Why?
|
| Prevalence | 15 | 2022 | 2839 | 0.360 |
Why?
|
| Cardiovascular System | 2 | 2024 | 136 | 0.360 |
Why?
|
| Product Surveillance, Postmarketing | 4 | 2020 | 73 | 0.360 |
Why?
|
| Warfarin | 6 | 2022 | 173 | 0.360 |
Why?
|
| Continuity of Patient Care | 3 | 2013 | 293 | 0.350 |
Why?
|
| Embolism | 2 | 2022 | 48 | 0.350 |
Why?
|
| Comparative Effectiveness Research | 6 | 2019 | 167 | 0.350 |
Why?
|
| Adult | 51 | 2025 | 40486 | 0.350 |
Why?
|
| Risk | 10 | 2015 | 911 | 0.350 |
Why?
|
| Methadone | 1 | 2013 | 122 | 0.350 |
Why?
|
| Drug-Eluting Stents | 3 | 2020 | 88 | 0.350 |
Why?
|
| Acculturation | 1 | 2012 | 54 | 0.350 |
Why?
|
| Hospital Records | 1 | 2011 | 10 | 0.350 |
Why?
|
| Convalescence | 1 | 2011 | 19 | 0.340 |
Why?
|
| Surveys and Questionnaires | 16 | 2021 | 6041 | 0.340 |
Why?
|
| Longitudinal Studies | 12 | 2020 | 2942 | 0.340 |
Why?
|
| Patient Education as Topic | 5 | 2019 | 771 | 0.330 |
Why?
|
| Epidemiologic Studies | 2 | 2017 | 68 | 0.330 |
Why?
|
| Employee Performance Appraisal | 1 | 2010 | 6 | 0.330 |
Why?
|
| Professionalism | 2 | 2021 | 26 | 0.330 |
Why?
|
| Mitral Valve | 2 | 2021 | 94 | 0.330 |
Why?
|
| Chi-Square Distribution | 11 | 2017 | 524 | 0.330 |
Why?
|
| Drug Costs | 2 | 2017 | 117 | 0.330 |
Why?
|
| Morbidity | 6 | 2022 | 322 | 0.330 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2021 | 299 | 0.330 |
Why?
|
| Nursing | 1 | 2010 | 37 | 0.320 |
Why?
|
| Pragmatic Clinical Trials as Topic | 3 | 2025 | 133 | 0.320 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2021 | 68 | 0.310 |
Why?
|
| Social Determinants of Health | 2 | 2024 | 305 | 0.310 |
Why?
|
| Heart-Assist Devices | 3 | 2021 | 568 | 0.310 |
Why?
|
| Kidney Diseases | 3 | 2009 | 427 | 0.310 |
Why?
|
| Severity of Illness Index | 14 | 2020 | 2922 | 0.310 |
Why?
|
| Colorado | 11 | 2021 | 4558 | 0.310 |
Why?
|
| Anticoagulants | 9 | 2022 | 729 | 0.310 |
Why?
|
| Hospitals, Urban | 7 | 2017 | 143 | 0.300 |
Why?
|
| Peripheral Arterial Disease | 3 | 2010 | 504 | 0.300 |
Why?
|
| Outpatients | 7 | 2018 | 447 | 0.300 |
Why?
|
| Healthy Lifestyle | 2 | 2020 | 37 | 0.300 |
Why?
|
| Drug Utilization | 6 | 2015 | 167 | 0.300 |
Why?
|
| Thrombolytic Therapy | 4 | 2016 | 161 | 0.300 |
Why?
|
| Contrast Media | 6 | 2024 | 492 | 0.300 |
Why?
|
| Pneumonia | 5 | 2017 | 629 | 0.290 |
Why?
|
| Thromboembolism | 2 | 2022 | 126 | 0.290 |
Why?
|
| Medicine, Chinese Traditional | 2 | 2019 | 8 | 0.290 |
Why?
|
| Cost Savings | 2 | 2019 | 85 | 0.280 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2019 | 24 | 0.280 |
Why?
|
| Health Literacy | 1 | 2011 | 184 | 0.280 |
Why?
|
| Health Status Indicators | 4 | 2020 | 167 | 0.280 |
Why?
|
| Water-Electrolyte Balance | 2 | 2007 | 37 | 0.280 |
Why?
|
| Device Approval | 2 | 2020 | 19 | 0.280 |
Why?
|
| Ischemic Attack, Transient | 2 | 2022 | 71 | 0.280 |
Why?
|
| Exercise Tolerance | 2 | 2008 | 282 | 0.270 |
Why?
|
| Clinical Competence | 4 | 2017 | 1237 | 0.270 |
Why?
|
| Heart Rate | 5 | 2021 | 853 | 0.270 |
Why?
|
| Radiology | 1 | 2010 | 174 | 0.270 |
Why?
|
| Sex Distribution | 5 | 2017 | 386 | 0.270 |
Why?
|
| Physicians | 5 | 2024 | 949 | 0.270 |
Why?
|
| Diagnostic Imaging | 5 | 2013 | 341 | 0.270 |
Why?
|
| Cause of Death | 6 | 2020 | 464 | 0.270 |
Why?
|
| Myocardial Perfusion Imaging | 2 | 2018 | 49 | 0.270 |
Why?
|
| Ezetimibe | 2 | 2018 | 24 | 0.270 |
Why?
|
| Fluorobenzenes | 1 | 2007 | 17 | 0.270 |
Why?
|
| Bundle-Branch Block | 4 | 2017 | 36 | 0.270 |
Why?
|
| Nurses, Community Health | 2 | 2019 | 38 | 0.260 |
Why?
|
| Hospitals, Veterans | 3 | 2016 | 258 | 0.260 |
Why?
|
| Emergency Service, Hospital | 6 | 2020 | 2325 | 0.260 |
Why?
|
| Survivors | 3 | 2012 | 519 | 0.260 |
Why?
|
| Hyperkalemia | 4 | 2016 | 35 | 0.260 |
Why?
|
| Hospitals, Low-Volume | 2 | 2024 | 26 | 0.250 |
Why?
|
| Systole | 5 | 2013 | 177 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2016 | 967 | 0.250 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2021 | 1406 | 0.250 |
Why?
|
| Epidemiologic Research Design | 1 | 2006 | 29 | 0.250 |
Why?
|
| Hospitals, High-Volume | 2 | 2024 | 50 | 0.250 |
Why?
|
| Attitude of Health Personnel | 3 | 2012 | 1180 | 0.240 |
Why?
|
| Coronary Vessels | 2 | 2019 | 246 | 0.240 |
Why?
|
| Inpatients | 8 | 2014 | 547 | 0.240 |
Why?
|
| Propensity Score | 7 | 2020 | 373 | 0.240 |
Why?
|
| Consensus | 5 | 2024 | 475 | 0.230 |
Why?
|
| Cholesterol, LDL | 5 | 2018 | 359 | 0.220 |
Why?
|
| Thoracic Surgery | 4 | 2021 | 144 | 0.220 |
Why?
|
| Echocardiography | 5 | 2019 | 644 | 0.220 |
Why?
|
| Contraindications | 8 | 2015 | 90 | 0.220 |
Why?
|
| Health Care Reform | 2 | 2018 | 107 | 0.220 |
Why?
|
| Troponin | 3 | 2017 | 49 | 0.220 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 177 | 0.220 |
Why?
|
| Prosthesis Design | 3 | 2016 | 355 | 0.220 |
Why?
|
| Antithrombins | 2 | 2017 | 69 | 0.220 |
Why?
|
| Bibliometrics | 2 | 2016 | 65 | 0.220 |
Why?
|
| Exercise | 5 | 2019 | 2183 | 0.220 |
Why?
|
| Monitoring, Physiologic | 3 | 2017 | 288 | 0.210 |
Why?
|
| Data Collection | 5 | 2017 | 635 | 0.210 |
Why?
|
| Efficiency, Organizational | 3 | 2018 | 140 | 0.210 |
Why?
|
| Polypharmacy | 2 | 2015 | 94 | 0.210 |
Why?
|
| Acute Disease | 11 | 2019 | 1029 | 0.210 |
Why?
|
| Hospitals, Rural | 4 | 2017 | 50 | 0.210 |
Why?
|
| Income | 3 | 2020 | 201 | 0.210 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2015 | 38 | 0.210 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2024 | 71 | 0.210 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2015 | 63 | 0.210 |
Why?
|
| Heart Conduction System | 3 | 2015 | 96 | 0.210 |
Why?
|
| Noncommunicable Diseases | 1 | 2024 | 20 | 0.200 |
Why?
|
| Pyrimidines | 1 | 2007 | 519 | 0.200 |
Why?
|
| Patient Care Planning | 1 | 2025 | 170 | 0.200 |
Why?
|
| Confidence Intervals | 4 | 2014 | 331 | 0.200 |
Why?
|
| Time-to-Treatment | 4 | 2019 | 242 | 0.200 |
Why?
|
| Sulfonamides | 1 | 2007 | 579 | 0.200 |
Why?
|
| Telemedicine | 4 | 2025 | 957 | 0.200 |
Why?
|
| Coronary Care Units | 3 | 2015 | 27 | 0.200 |
Why?
|
| Professional Practice Gaps | 2 | 2020 | 15 | 0.190 |
Why?
|
| Stents | 5 | 2016 | 557 | 0.190 |
Why?
|
| Administrative Claims, Healthcare | 2 | 2020 | 28 | 0.190 |
Why?
|
| Cross Infection | 2 | 2024 | 263 | 0.190 |
Why?
|
| Referral and Consultation | 5 | 2017 | 852 | 0.190 |
Why?
|
| Treatment Refusal | 3 | 2008 | 98 | 0.190 |
Why?
|
| Periodicals as Topic | 2 | 2016 | 206 | 0.190 |
Why?
|
| Thiazoles | 1 | 2003 | 139 | 0.190 |
Why?
|
| Canada | 6 | 2026 | 432 | 0.180 |
Why?
|
| Skilled Nursing Facilities | 2 | 2017 | 151 | 0.180 |
Why?
|
| Computed Tomography Angiography | 2 | 2020 | 146 | 0.180 |
Why?
|
| Biomarkers | 15 | 2025 | 4261 | 0.180 |
Why?
|
| Pericardial Effusion | 1 | 2022 | 21 | 0.180 |
Why?
|
| Biomedical Research | 1 | 2008 | 712 | 0.180 |
Why?
|
| Renal Insufficiency | 1 | 2004 | 172 | 0.180 |
Why?
|
| Technology Transfer | 1 | 2021 | 9 | 0.170 |
Why?
|
| Primary Health Care | 3 | 2025 | 1730 | 0.170 |
Why?
|
| Culturally Competent Care | 2 | 2019 | 73 | 0.170 |
Why?
|
| Sex Characteristics | 2 | 2022 | 776 | 0.170 |
Why?
|
| Catheter Ablation | 2 | 2017 | 354 | 0.170 |
Why?
|
| Patient Participation | 2 | 2016 | 428 | 0.170 |
Why?
|
| Hypercholesterolemia | 1 | 2022 | 93 | 0.170 |
Why?
|
| Accreditation | 2 | 2020 | 101 | 0.170 |
Why?
|
| Administrative Personnel | 2 | 2019 | 33 | 0.170 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2019 | 103 | 0.170 |
Why?
|
| Models, Statistical | 5 | 2019 | 677 | 0.170 |
Why?
|
| Risk Reduction Behavior | 2 | 2020 | 215 | 0.170 |
Why?
|
| Mass Screening | 4 | 2019 | 1348 | 0.170 |
Why?
|
| Fibrinolytic Agents | 4 | 2022 | 290 | 0.170 |
Why?
|
| Manufacturing Industry | 1 | 2020 | 6 | 0.160 |
Why?
|
| Physician-Patient Relations | 3 | 2014 | 589 | 0.160 |
Why?
|
| Long Term Adverse Effects | 1 | 2020 | 13 | 0.160 |
Why?
|
| Decision Making | 7 | 2016 | 973 | 0.160 |
Why?
|
| Creatine Kinase, MB Form | 2 | 2017 | 6 | 0.160 |
Why?
|
| Geographic Mapping | 1 | 2020 | 29 | 0.160 |
Why?
|
| Ethics, Medical | 1 | 2021 | 90 | 0.160 |
Why?
|
| Recovery of Function | 6 | 2020 | 715 | 0.160 |
Why?
|
| Prosthesis Failure | 2 | 2018 | 125 | 0.160 |
Why?
|
| Social Class | 3 | 2019 | 265 | 0.160 |
Why?
|
| Managed Care Programs | 2 | 2011 | 140 | 0.160 |
Why?
|
| Benzoxazoles | 1 | 2020 | 19 | 0.160 |
Why?
|
| Bacteremia | 2 | 2021 | 222 | 0.150 |
Why?
|
| Femoral Artery | 1 | 2021 | 190 | 0.150 |
Why?
|
| Young Adult | 12 | 2022 | 14119 | 0.150 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2010 | 84 | 0.150 |
Why?
|
| New York | 2 | 2017 | 127 | 0.150 |
Why?
|
| Amyloidosis | 1 | 2020 | 44 | 0.150 |
Why?
|
| Neprilysin | 1 | 2020 | 47 | 0.150 |
Why?
|
| Body Mass Index | 5 | 2021 | 2419 | 0.150 |
Why?
|
| Reoperation | 2 | 2020 | 624 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2014 | 2019 | 0.150 |
Why?
|
| International Cooperation | 2 | 2018 | 197 | 0.150 |
Why?
|
| Self Care | 2 | 2019 | 389 | 0.150 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2021 | 387 | 0.150 |
Why?
|
| Models, Economic | 1 | 2019 | 61 | 0.150 |
Why?
|
| Health Care Surveys | 5 | 2019 | 537 | 0.150 |
Why?
|
| Digoxin | 1 | 2019 | 27 | 0.150 |
Why?
|
| Reproducibility of Results | 9 | 2021 | 3414 | 0.150 |
Why?
|
| Reimbursement Mechanisms | 1 | 2019 | 79 | 0.150 |
Why?
|
| Information Storage and Retrieval | 1 | 2020 | 122 | 0.150 |
Why?
|
| Cardiology Service, Hospital | 1 | 2019 | 29 | 0.140 |
Why?
|
| Multiple Chronic Conditions | 1 | 2019 | 34 | 0.140 |
Why?
|
| Thinness | 1 | 2019 | 98 | 0.140 |
Why?
|
| United States Food and Drug Administration | 2 | 2020 | 205 | 0.140 |
Why?
|
| Vena Cava Filters | 2 | 2018 | 64 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 221 | 0.140 |
Why?
|
| Disease Progression | 6 | 2013 | 2847 | 0.140 |
Why?
|
| Return to Work | 1 | 2018 | 21 | 0.140 |
Why?
|
| Frailty | 1 | 2022 | 200 | 0.140 |
Why?
|
| Anticholesteremic Agents | 2 | 2017 | 154 | 0.140 |
Why?
|
| Nursing Staff | 1 | 2019 | 40 | 0.140 |
Why?
|
| Medical Records | 5 | 2016 | 191 | 0.140 |
Why?
|
| Nutrition Surveys | 4 | 2023 | 280 | 0.140 |
Why?
|
| Fraud | 1 | 2018 | 11 | 0.140 |
Why?
|
| Equipment Safety | 2 | 2015 | 38 | 0.140 |
Why?
|
| Regression Analysis | 6 | 2017 | 998 | 0.140 |
Why?
|
| Drug Utilization Review | 2 | 2012 | 61 | 0.140 |
Why?
|
| Medical Record Linkage | 2 | 2015 | 68 | 0.140 |
Why?
|
| Medical Overuse | 1 | 2018 | 30 | 0.140 |
Why?
|
| Transitional Care | 1 | 2018 | 45 | 0.140 |
Why?
|
| Ticlopidine | 2 | 2015 | 51 | 0.140 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2018 | 48 | 0.140 |
Why?
|
| Liability, Legal | 1 | 2018 | 42 | 0.130 |
Why?
|
| Coronary Stenosis | 1 | 2018 | 38 | 0.130 |
Why?
|
| Data Mining | 1 | 2018 | 115 | 0.130 |
Why?
|
| Dabigatran | 1 | 2017 | 29 | 0.130 |
Why?
|
| Health Services Accessibility | 4 | 2019 | 1098 | 0.130 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2008 | 122 | 0.130 |
Why?
|
| Subacute Care | 1 | 2018 | 82 | 0.130 |
Why?
|
| Socioeconomic Factors | 7 | 2019 | 1322 | 0.130 |
Why?
|
| Arteriosclerosis | 1 | 2017 | 83 | 0.130 |
Why?
|
| Patient Care Management | 1 | 2017 | 56 | 0.130 |
Why?
|
| Heart Arrest | 3 | 2021 | 406 | 0.130 |
Why?
|
| Depression | 6 | 2012 | 1561 | 0.130 |
Why?
|
| Health Surveys | 3 | 2015 | 517 | 0.130 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 267 | 0.130 |
Why?
|
| Postoperative Care | 4 | 2013 | 286 | 0.130 |
Why?
|
| Vaccines | 1 | 2022 | 388 | 0.130 |
Why?
|
| Telemetry | 1 | 2017 | 40 | 0.130 |
Why?
|
| Simvastatin | 1 | 2017 | 59 | 0.130 |
Why?
|
| Patient Preference | 2 | 2026 | 226 | 0.130 |
Why?
|
| Elective Surgical Procedures | 1 | 2018 | 201 | 0.130 |
Why?
|
| Pulmonary Embolism | 2 | 2018 | 241 | 0.130 |
Why?
|
| Recurrence | 3 | 2018 | 1136 | 0.120 |
Why?
|
| Educational Status | 1 | 2019 | 463 | 0.120 |
Why?
|
| Insurance Coverage | 1 | 2018 | 243 | 0.120 |
Why?
|
| Dyslipidemias | 1 | 2018 | 182 | 0.120 |
Why?
|
| Policy | 2 | 2022 | 147 | 0.120 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2015 | 4 | 0.120 |
Why?
|
| Factor Xa Inhibitors | 1 | 2017 | 187 | 0.120 |
Why?
|
| Veterans Health | 1 | 2017 | 189 | 0.110 |
Why?
|
| Documentation | 1 | 2017 | 198 | 0.110 |
Why?
|
| Pyridones | 1 | 2017 | 201 | 0.110 |
Why?
|
| Blood Coagulation | 1 | 2017 | 269 | 0.110 |
Why?
|
| Equipment and Supplies | 1 | 2015 | 35 | 0.110 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2019 | 496 | 0.110 |
Why?
|
| Kidney | 3 | 2023 | 1495 | 0.110 |
Why?
|
| Clinical Chemistry Tests | 1 | 2015 | 6 | 0.110 |
Why?
|
| Sepsis | 1 | 2021 | 643 | 0.110 |
Why?
|
| Obesity | 3 | 2019 | 3070 | 0.110 |
Why?
|
| Drug Substitution | 1 | 2015 | 63 | 0.110 |
Why?
|
| Rivaroxaban | 1 | 2017 | 268 | 0.110 |
Why?
|
| Blood Vessels | 1 | 2016 | 167 | 0.110 |
Why?
|
| Drug Monitoring | 2 | 2021 | 396 | 0.110 |
Why?
|
| Mandatory Reporting | 1 | 2015 | 45 | 0.110 |
Why?
|
| Weight Reduction Programs | 1 | 2016 | 138 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 120 | 0.110 |
Why?
|
| Japan | 3 | 2021 | 145 | 0.110 |
Why?
|
| Qualitative Research | 3 | 2019 | 1668 | 0.110 |
Why?
|
| Linear Models | 4 | 2017 | 845 | 0.110 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2017 | 771 | 0.110 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2015 | 79 | 0.100 |
Why?
|
| Aortic Valve Stenosis | 1 | 2017 | 255 | 0.100 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2014 | 24 | 0.100 |
Why?
|
| Aortic Valve | 1 | 2017 | 364 | 0.100 |
Why?
|
| Patient Compliance | 3 | 2008 | 587 | 0.100 |
Why?
|
| Endarterectomy, Carotid | 1 | 2014 | 60 | 0.100 |
Why?
|
| Preventive Health Services | 1 | 2015 | 154 | 0.100 |
Why?
|
| Adolescent | 9 | 2021 | 22405 | 0.100 |
Why?
|
| Single-Blind Method | 3 | 2019 | 319 | 0.100 |
Why?
|
| Urination Disorders | 1 | 2013 | 15 | 0.100 |
Why?
|
| Residence Characteristics | 5 | 2015 | 374 | 0.100 |
Why?
|
| Pulmonary Valve | 1 | 2015 | 100 | 0.100 |
Why?
|
| Administration, Oral | 5 | 2017 | 851 | 0.100 |
Why?
|
| Workplace | 1 | 2015 | 270 | 0.100 |
Why?
|
| Community Health Services | 2 | 2013 | 231 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2017 | 512 | 0.100 |
Why?
|
| Cerebral Hemorrhage | 1 | 2014 | 120 | 0.100 |
Why?
|
| Venous Thromboembolism | 1 | 2018 | 326 | 0.100 |
Why?
|
| Ventricular Premature Complexes | 1 | 2013 | 37 | 0.100 |
Why?
|
| Myocardium | 2 | 2015 | 928 | 0.100 |
Why?
|
| Patient Safety | 2 | 2018 | 353 | 0.100 |
Why?
|
| Lung Transplantation | 1 | 2016 | 329 | 0.100 |
Why?
|
| Hirudins | 1 | 2013 | 51 | 0.090 |
Why?
|
| Cardiac Rehabilitation | 2 | 2017 | 46 | 0.090 |
Why?
|
| Body Weight | 1 | 2017 | 968 | 0.090 |
Why?
|
| Gait | 1 | 2016 | 312 | 0.090 |
Why?
|
| Observation | 1 | 2012 | 54 | 0.090 |
Why?
|
| ROC Curve | 3 | 2019 | 618 | 0.090 |
Why?
|
| Pacific States | 1 | 2012 | 7 | 0.090 |
Why?
|
| New England | 1 | 2012 | 37 | 0.090 |
Why?
|
| Communication | 1 | 2019 | 972 | 0.090 |
Why?
|
| Poisson Distribution | 2 | 2012 | 78 | 0.090 |
Why?
|
| Health Maintenance Organizations | 1 | 2012 | 105 | 0.090 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 1044 | 0.090 |
Why?
|
| Erythrocyte Indices | 1 | 2012 | 33 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 5 | 2017 | 638 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2016 | 941 | 0.090 |
Why?
|
| Patient Satisfaction | 2 | 2025 | 707 | 0.090 |
Why?
|
| Reimbursement, Incentive | 2 | 2015 | 42 | 0.090 |
Why?
|
| Activities of Daily Living | 3 | 2012 | 441 | 0.090 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 170 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 881 | 0.090 |
Why?
|
| Pregnancy | 2 | 2022 | 7122 | 0.090 |
Why?
|
| Drug Resistance | 1 | 2012 | 145 | 0.090 |
Why?
|
| National Health Programs | 2 | 2015 | 23 | 0.090 |
Why?
|
| Rural Population | 4 | 2019 | 657 | 0.090 |
Why?
|
| Phlebotomy | 1 | 2011 | 22 | 0.090 |
Why?
|
| Evaluation Studies as Topic | 1 | 2011 | 164 | 0.090 |
Why?
|
| Hospitals, Teaching | 3 | 2021 | 119 | 0.080 |
Why?
|
| Social Environment | 1 | 2013 | 253 | 0.080 |
Why?
|
| Angioplasty | 1 | 2011 | 50 | 0.080 |
Why?
|
| History, 21st Century | 1 | 2012 | 220 | 0.080 |
Why?
|
| Clinical Medicine | 1 | 2011 | 26 | 0.080 |
Why?
|
| Laboratories, Hospital | 1 | 2011 | 13 | 0.080 |
Why?
|
| Independent Living | 1 | 2012 | 116 | 0.080 |
Why?
|
| Carotid Artery Diseases | 1 | 2011 | 70 | 0.080 |
Why?
|
| Opiate Substitution Treatment | 1 | 2013 | 186 | 0.080 |
Why?
|
| History, 20th Century | 1 | 2012 | 327 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2026 | 1886 | 0.080 |
Why?
|
| Physical Fitness | 1 | 2012 | 207 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2012 | 516 | 0.080 |
Why?
|
| Eligibility Determination | 3 | 2017 | 72 | 0.080 |
Why?
|
| Aftercare | 2 | 2022 | 222 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 562 | 0.080 |
Why?
|
| Sickness Impact Profile | 2 | 2012 | 62 | 0.080 |
Why?
|
| Potassium | 2 | 2013 | 152 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 1505 | 0.080 |
Why?
|
| Diuretics | 2 | 2012 | 68 | 0.080 |
Why?
|
| Heart Transplantation | 1 | 2016 | 674 | 0.080 |
Why?
|
| Caregivers | 1 | 2019 | 1062 | 0.080 |
Why?
|
| Depressive Disorder | 2 | 2010 | 386 | 0.080 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 1363 | 0.080 |
Why?
|
| Asia | 2 | 2020 | 71 | 0.070 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2013 | 337 | 0.070 |
Why?
|
| Poverty | 1 | 2013 | 522 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2013 | 691 | 0.070 |
Why?
|
| Cost of Illness | 3 | 2015 | 322 | 0.070 |
Why?
|
| Probability | 1 | 2010 | 309 | 0.070 |
Why?
|
| Overweight | 2 | 2019 | 606 | 0.070 |
Why?
|
| Public Health Informatics | 1 | 2008 | 10 | 0.070 |
Why?
|
| Prosthesis-Related Infections | 1 | 2010 | 98 | 0.070 |
Why?
|
| Cardiotonic Agents | 2 | 2013 | 94 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2012 | 431 | 0.070 |
Why?
|
| Observational Studies as Topic | 2 | 2020 | 131 | 0.070 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2008 | 82 | 0.070 |
Why?
|
| Urban Population | 3 | 2017 | 493 | 0.070 |
Why?
|
| Emergency Medical Services | 1 | 2015 | 695 | 0.070 |
Why?
|
| California | 2 | 2006 | 471 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2010 | 252 | 0.070 |
Why?
|
| Rosuvastatin Calcium | 1 | 2007 | 21 | 0.070 |
Why?
|
| Internal Medicine | 1 | 2010 | 278 | 0.070 |
Why?
|
| Atrial Flutter | 1 | 2008 | 47 | 0.070 |
Why?
|
| Proprotein Convertase 9 | 2 | 2018 | 87 | 0.070 |
Why?
|
| Rehabilitation | 1 | 2007 | 20 | 0.070 |
Why?
|
| Palliative Care | 2 | 2007 | 1011 | 0.060 |
Why?
|
| Certificate of Need | 1 | 2007 | 2 | 0.060 |
Why?
|
| Reimbursement, Disproportionate Share | 1 | 2007 | 1 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2017 | 3910 | 0.060 |
Why?
|
| Retreatment | 2 | 2020 | 77 | 0.060 |
Why?
|
| Protective Factors | 2 | 2018 | 99 | 0.060 |
Why?
|
| Insulin | 3 | 2013 | 2502 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 286 | 0.060 |
Why?
|
| Reperfusion | 1 | 2006 | 54 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2007 | 365 | 0.060 |
Why?
|
| Renal Dialysis | 3 | 2016 | 465 | 0.060 |
Why?
|
| Cerebrovascular Disorders | 2 | 2017 | 106 | 0.060 |
Why?
|
| Blood Urea Nitrogen | 1 | 2006 | 53 | 0.060 |
Why?
|
| Edema | 1 | 2007 | 124 | 0.060 |
Why?
|
| Terminology as Topic | 2 | 2024 | 255 | 0.060 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2006 | 154 | 0.060 |
Why?
|
| Interviews as Topic | 3 | 2021 | 905 | 0.060 |
Why?
|
| Vulnerable Populations | 1 | 2007 | 175 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 217 | 0.060 |
Why?
|
| Body Temperature | 1 | 2006 | 226 | 0.060 |
Why?
|
| International Classification of Diseases | 2 | 2021 | 147 | 0.060 |
Why?
|
| Endocarditis | 2 | 2010 | 40 | 0.050 |
Why?
|
| Opioid-Related Disorders | 1 | 2013 | 601 | 0.050 |
Why?
|
| Heart Valves | 1 | 2005 | 43 | 0.050 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2005 | 109 | 0.050 |
Why?
|
| Atrial Function, Left | 1 | 2024 | 9 | 0.050 |
Why?
|
| Specialization | 1 | 2005 | 136 | 0.050 |
Why?
|
| Appointments and Schedules | 1 | 2025 | 96 | 0.050 |
Why?
|
| Hospital-Physician Relations | 1 | 2024 | 4 | 0.050 |
Why?
|
| Hypoglycemia | 1 | 2009 | 479 | 0.050 |
Why?
|
| Motivation | 2 | 2019 | 601 | 0.050 |
Why?
|
| Cultural Characteristics | 1 | 2004 | 69 | 0.050 |
Why?
|
| Databases as Topic | 3 | 2010 | 71 | 0.050 |
Why?
|
| Medicine | 1 | 2005 | 125 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2025 | 408 | 0.050 |
Why?
|
| Weight Gain | 1 | 2007 | 557 | 0.050 |
Why?
|
| Medication Therapy Management | 2 | 2017 | 72 | 0.050 |
Why?
|
| Ibuprofen | 1 | 2003 | 84 | 0.050 |
Why?
|
| Research | 2 | 2008 | 431 | 0.050 |
Why?
|
| Michigan | 2 | 2015 | 137 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 779 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2012 | 2753 | 0.050 |
Why?
|
| Health Services Needs and Demand | 2 | 2016 | 276 | 0.050 |
Why?
|
| Health Promotion | 1 | 2008 | 771 | 0.040 |
Why?
|
| Weight Loss | 1 | 2007 | 839 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2026 | 1103 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2003 | 223 | 0.040 |
Why?
|
| Diagnosis-Related Groups | 1 | 2021 | 35 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2004 | 1301 | 0.040 |
Why?
|
| Maryland | 1 | 2021 | 67 | 0.040 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 136 | 0.040 |
Why?
|
| Reminder Systems | 1 | 2022 | 140 | 0.040 |
Why?
|
| Smoking Cessation | 2 | 2020 | 436 | 0.040 |
Why?
|
| Assisted Circulation | 1 | 2021 | 26 | 0.040 |
Why?
|
| Medical Device Legislation | 1 | 2020 | 3 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 338 | 0.040 |
Why?
|
| Standard of Care | 1 | 2021 | 81 | 0.040 |
Why?
|
| Decision Trees | 2 | 2016 | 79 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2020 | 139 | 0.040 |
Why?
|
| Matched-Pair Analysis | 1 | 2020 | 37 | 0.040 |
Why?
|
| Family Practice | 1 | 2004 | 402 | 0.040 |
Why?
|
| Coronary Thrombosis | 1 | 2020 | 25 | 0.040 |
Why?
|
| Latin America | 1 | 2020 | 95 | 0.040 |
Why?
|
| Coronary Restenosis | 1 | 2020 | 22 | 0.040 |
Why?
|
| Medicaid | 2 | 2017 | 464 | 0.040 |
Why?
|
| Argentina | 1 | 2019 | 30 | 0.040 |
Why?
|
| Case-Control Studies | 3 | 2022 | 3603 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2008 | 1154 | 0.040 |
Why?
|
| Brazil | 1 | 2019 | 182 | 0.040 |
Why?
|
| Evidence-Based Practice | 2 | 2013 | 229 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2015 | 919 | 0.040 |
Why?
|
| Health Personnel | 2 | 2018 | 746 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 1268 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2019 | 85 | 0.040 |
Why?
|
| Health Communication | 1 | 2019 | 54 | 0.040 |
Why?
|
| Hypertension, Pulmonary | 1 | 2010 | 1948 | 0.040 |
Why?
|
| United States Government Agencies | 1 | 2018 | 5 | 0.040 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2020 | 217 | 0.030 |
Why?
|
| Retirement | 1 | 2018 | 35 | 0.030 |
Why?
|
| Clinical Audit | 1 | 2018 | 14 | 0.030 |
Why?
|
| Hospital Charges | 1 | 2018 | 46 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2006 | 1241 | 0.030 |
Why?
|
| Sample Size | 1 | 2018 | 120 | 0.030 |
Why?
|
| Malpractice | 1 | 2018 | 44 | 0.030 |
Why?
|
| Internationality | 1 | 2018 | 154 | 0.030 |
Why?
|
| F Factor | 1 | 2017 | 4 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 343 | 0.030 |
Why?
|
| Puerperal Disorders | 1 | 2018 | 37 | 0.030 |
Why?
|
| Health Facility Size | 1 | 2017 | 13 | 0.030 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2018 | 83 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 170 | 0.030 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 83 | 0.030 |
Why?
|
| Atherosclerosis | 1 | 2021 | 409 | 0.030 |
Why?
|
| Drug Approval | 1 | 2017 | 91 | 0.030 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2017 | 97 | 0.030 |
Why?
|
| Arabidopsis Proteins | 1 | 2017 | 76 | 0.030 |
Why?
|
| Renin-Angiotensin System | 1 | 2017 | 79 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 368 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2010 | 379 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2008 | 284 | 0.030 |
Why?
|
| Algorithms | 2 | 2015 | 1843 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 616 | 0.030 |
Why?
|
| Spain | 1 | 2015 | 49 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 287 | 0.030 |
Why?
|
| Cooperative Behavior | 2 | 2009 | 464 | 0.030 |
Why?
|
| Health Care Sector | 1 | 2015 | 26 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2015 | 53 | 0.030 |
Why?
|
| Pentetic Acid | 1 | 1995 | 13 | 0.030 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 1995 | 5 | 0.030 |
Why?
|
| Hospital Bed Capacity | 1 | 2015 | 28 | 0.030 |
Why?
|
| Classification | 1 | 2015 | 43 | 0.030 |
Why?
|
| Industry | 1 | 2015 | 42 | 0.030 |
Why?
|
| Health Care Rationing | 1 | 2015 | 56 | 0.030 |
Why?
|
| Life Style | 1 | 2017 | 481 | 0.030 |
Why?
|
| Urban Health Services | 1 | 2015 | 71 | 0.030 |
Why?
|
| Conflict of Interest | 1 | 2015 | 54 | 0.030 |
Why?
|
| Journal Impact Factor | 1 | 2015 | 29 | 0.030 |
Why?
|
| Operative Time | 1 | 2015 | 181 | 0.030 |
Why?
|
| Health Behavior | 2 | 2015 | 786 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2015 | 135 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2015 | 129 | 0.030 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2015 | 60 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3887 | 0.030 |
Why?
|
| Access to Information | 1 | 2015 | 47 | 0.030 |
Why?
|
| Peer Review, Research | 1 | 2015 | 36 | 0.030 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1995 | 69 | 0.030 |
Why?
|
| Academic Medical Centers | 2 | 2009 | 545 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 2033 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 249 | 0.030 |
Why?
|
| Markov Chains | 2 | 2009 | 130 | 0.030 |
Why?
|
| Age Distribution | 2 | 2005 | 402 | 0.030 |
Why?
|
| Ischemia | 1 | 2018 | 422 | 0.030 |
Why?
|
| Chronic Disease | 3 | 2005 | 1810 | 0.030 |
Why?
|
| Physical Examination | 1 | 2015 | 240 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 282 | 0.030 |
Why?
|
| Drug Hypersensitivity | 1 | 2015 | 89 | 0.030 |
Why?
|
| Organometallic Compounds | 1 | 1995 | 113 | 0.030 |
Why?
|
| Ownership | 1 | 2015 | 115 | 0.030 |
Why?
|
| Jejunum | 1 | 1994 | 36 | 0.030 |
Why?
|
| Rural Health Services | 1 | 2015 | 139 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2014 | 89 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 551 | 0.020 |
Why?
|
| Vaccination | 1 | 2022 | 1419 | 0.020 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2013 | 17 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 287 | 0.020 |
Why?
|
| Observer Variation | 1 | 2014 | 355 | 0.020 |
Why?
|
| Research Personnel | 1 | 2015 | 185 | 0.020 |
Why?
|
| Intestinal Absorption | 1 | 1994 | 103 | 0.020 |
Why?
|
| Pandemics | 1 | 2021 | 1700 | 0.020 |
Why?
|
| Triage | 1 | 2015 | 249 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 827 | 0.020 |
Why?
|
| Food | 1 | 1994 | 148 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2012 | 71 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2013 | 115 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 741 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 422 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2015 | 717 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1997 | 1113 | 0.020 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2013 | 103 | 0.020 |
Why?
|
| Medical Audit | 1 | 2012 | 77 | 0.020 |
Why?
|
| Electrodes, Implanted | 1 | 2013 | 115 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2012 | 55 | 0.020 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1995 | 260 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2015 | 355 | 0.020 |
Why?
|
| Foundations | 1 | 2011 | 27 | 0.020 |
Why?
|
| Dementia | 1 | 2015 | 319 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 990 | 0.020 |
Why?
|
| Self Report | 1 | 2015 | 869 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2015 | 574 | 0.020 |
Why?
|
| Ankle Brachial Index | 1 | 2010 | 41 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2017 | 781 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 1021 | 0.020 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 24 | 0.020 |
Why?
|
| Patients | 1 | 2011 | 182 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2010 | 66 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2010 | 80 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 1467 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 1995 | 0.020 |
Why?
|
| Life Tables | 1 | 2009 | 21 | 0.020 |
Why?
|
| Aortic Diseases | 1 | 2010 | 125 | 0.020 |
Why?
|
| Leadership | 1 | 2013 | 400 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2009 | 73 | 0.020 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2008 | 103 | 0.020 |
Why?
|
| Regional Health Planning | 1 | 2008 | 8 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 1994 | 675 | 0.020 |
Why?
|
| Public Health | 1 | 2013 | 569 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 1995 | 978 | 0.020 |
Why?
|
| Drug Labeling | 1 | 2007 | 37 | 0.020 |
Why?
|
| Time and Motion Studies | 1 | 2007 | 28 | 0.020 |
Why?
|
| Vitamin E | 1 | 1988 | 123 | 0.020 |
Why?
|
| Melanoma, Experimental | 1 | 1988 | 109 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2015 | 1176 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2013 | 915 | 0.020 |
Why?
|
| Prospective Payment System | 1 | 2007 | 15 | 0.020 |
Why?
|
| Fees, Medical | 1 | 2006 | 9 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 2008 | 143 | 0.020 |
Why?
|
| Phenotype | 1 | 2015 | 3147 | 0.020 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2008 | 107 | 0.020 |
Why?
|
| Disclosure | 1 | 2007 | 84 | 0.020 |
Why?
|
| North Carolina | 1 | 2006 | 126 | 0.020 |
Why?
|
| Syndrome | 1 | 2007 | 379 | 0.020 |
Why?
|
| Europe | 1 | 2007 | 419 | 0.020 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2006 | 82 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2008 | 222 | 0.010 |
Why?
|
| Lovastatin | 1 | 2006 | 37 | 0.010 |
Why?
|
| Protein Kinases | 1 | 1988 | 314 | 0.010 |
Why?
|
| Pravastatin | 1 | 2006 | 44 | 0.010 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2006 | 54 | 0.010 |
Why?
|
| Heptanoic Acids | 1 | 2006 | 67 | 0.010 |
Why?
|
| Exercise Therapy | 1 | 2010 | 475 | 0.010 |
Why?
|
| Demography | 1 | 2006 | 287 | 0.010 |
Why?
|
| Hematocrit | 1 | 2005 | 108 | 0.010 |
Why?
|
| Midwestern United States | 1 | 2004 | 45 | 0.010 |
Why?
|
| Northwestern United States | 1 | 2004 | 58 | 0.010 |
Why?
|
| Pyrroles | 1 | 2006 | 213 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 768 | 0.010 |
Why?
|
| Diabetic Nephropathies | 1 | 2007 | 318 | 0.010 |
Why?
|
| Diastole | 1 | 2004 | 142 | 0.010 |
Why?
|
| Veterans | 1 | 2015 | 1614 | 0.010 |
Why?
|
| Social Support | 1 | 2007 | 650 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2003 | 401 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2004 | 426 | 0.010 |
Why?
|
| Indoles | 1 | 2006 | 504 | 0.010 |
Why?
|
| Pyridines | 1 | 2006 | 603 | 0.010 |
Why?
|
| Child | 2 | 2013 | 22599 | 0.010 |
Why?
|
| Counseling | 1 | 2004 | 405 | 0.010 |
Why?
|
| Neoplasms | 1 | 2015 | 2873 | 0.010 |
Why?
|
| Quality-Adjusted Life Years | 1 | 1999 | 122 | 0.010 |
Why?
|
| Endocarditis, Bacterial | 1 | 1999 | 46 | 0.010 |
Why?
|
| Echocardiography, Transesophageal | 1 | 1999 | 132 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2004 | 690 | 0.010 |
Why?
|
| Alcoholism | 1 | 2004 | 813 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2013 | 11789 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1999 | 1501 | 0.010 |
Why?
|
| Cystectomy | 1 | 1995 | 42 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 1995 | 70 | 0.010 |
Why?
|
| Prostatectomy | 1 | 1995 | 94 | 0.010 |
Why?
|
| Jejunostomy | 1 | 1994 | 14 | 0.010 |
Why?
|
| Intestinal Fistula | 1 | 1994 | 18 | 0.010 |
Why?
|
| Image Enhancement | 1 | 1995 | 199 | 0.010 |
Why?
|
| Bupivacaine | 1 | 1994 | 40 | 0.010 |
Why?
|
| Enteric Nervous System | 1 | 1994 | 26 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1995 | 503 | 0.010 |
Why?
|
| Dogs | 1 | 1994 | 438 | 0.010 |
Why?
|
| Nerve Block | 1 | 1994 | 106 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 1994 | 292 | 0.010 |
Why?
|
| Prostaglandins A | 1 | 1988 | 9 | 0.000 |
Why?
|
| Tocopherols | 1 | 1988 | 31 | 0.000 |
Why?
|
| Cyclic AMP | 1 | 1988 | 205 | 0.000 |
Why?
|
| Tumor Cells, Cultured | 1 | 1988 | 881 | 0.000 |
Why?
|
| Cell Survival | 1 | 1988 | 1092 | 0.000 |
Why?
|
| Animals | 2 | 1994 | 37948 | 0.000 |
Why?
|
| Mice | 1 | 1988 | 18261 | 0.000 |
Why?
|